- GMRx2 is an innovative single pill combination of three medicines designed to deliver the blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, supported by an established safety profile
- George Medicines receives upfront licensing fee and is eligible for regulatory and commercial milestone payments, along with a future recurring revenue stream through stepped royalties in Southeast Asia
- Fourth licensing and supply agreement for GMRx2 reflects continued global partner interest, with further partnerships anticipated as George Medicines advances its strategy to expand global patient access
London, UK, 25 February 2026 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Orient EuroPharma (“OEP”) (TWO: 4120), a leading multinational pharmaceutical company headquartered in Taiwan, granting OEP exclusive rights to seek regulatory approval of, and to commercialize, GMRx2 in Southeast Asia.
GMRx2 is an innovative single pill combination of three medicines, telmisartan, amlodipine and indapamide, for the treatment of hypertension, developed in three doses, including two doses that are lower than those currently available in single pill combinations. Its multi-mechanism approach and available doses are formulated to deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, with the safety profile of established antihypertensive medications.
Under the terms of the licensing agreement, George Medicines will receive an upfront licensing fee and is eligible for regulatory and commercial milestone payments, as well as a future recurring revenue stream through a stepped royalty rate on sales of GMRx2 in the licensed territory. In return, OEP is granted a license to exclusively commercialize GMRx2, supplied by George Medicines. OEP is responsible for seeking regulatory approval of GMRx2, with support from George Medicines.
Mark Mallon, Chief Executive Officer of George Medicines, said: “This exclusive licensing and supply agreement with Orient EuroPharma marks another important step in the global expansion of GMRx2, adding Southeast Asia to our growing network of partners across the US, Canada, Mexico, Colombia, Central America and Brazil. Hypertension remains a major and growing health challenge across Southeast Asia, with high prevalence, and low control rates. GMRx2’s proven clinical efficacy, multiple dosing options, and established safety profile position it well to address unmet need in hypertension management and we look forward to working with Orient EuroPharma to expand access to this important therapy across the region.”
Calvin Tsai, Chief Executive Officer of Orient EuroPharma, said: “We are pleased to partner with George Medicines as part of the continued global expansion of GMRx2. This agreement reflects our shared commitment to improving cardiovascular outcomes and brings an innovative triple combination therapy to Southeast Asia. With our established regional presence and expertise in regulatory and commercial execution, we are well positioned to support the development and launch of GMRx2 and to help broaden patient access across Southeast Asia.”
This agreement further strengthens George Medicines’ global commercialization strategy for GMRx2, following licensing and supply agreements with Azurity Pharmaceuticals in the US, Bausch Health in Canada, Mexico, Colombia and Central America, and Biolab Farmacêutica in Brazil. Together, these partnerships demonstrate growing global interest in GMRx2 and its potential to address unmet needs in hypertension treatment. Additional partnerships are anticipated as part of George Medicines’ commitment to bringing the benefits of GMRx2 to patients worldwide.
George Medicines is an independent spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes with a focus on addressing global health inequity. The Company is backed by George Health, the commercial arm of The George Institute, and Brandon Capital, Australia’s leading life sciences venture capital firm.
Ends
About GMRx2
GMRx2 is a combination tablet of telmisartan, an angiotensin II receptor blocker, amlodipine, a dihydropyridine calcium channel blocker and indapamide, a thiazide-like diuretic, available in three dosage forms – 10/1.25/0.625 mg; 20/2.5/1.25 mg and 40/5/2.5 mg.
Its development is backed by a comprehensive clinical program, including two pivotal Phase III studies, published in 2024 in the Journal of the American College of Cardiology and The Lancet.
In these trials the triple combination demonstrated significantly reduced blood pressure (BP) and improved BP control rates, when compared against dual therapy and against placebo. In both trials, tolerability was good, with no increase in withdrawal from treatment due to adverse events.
GMRx2 was investigated in the Nigerian VERONICA trial, which compared the triple combination with standard of care and reported better BP lowering among those receiving GMRx2, with good tolerability compared to the standard of care protocol.
A global trial investigating the potential of GMRx2 for the prevention of stroke in people who have had intracerebral hemorrhage (the most severe type of stroke) is ongoing.
About George Medicines
George Medicines is a late-stage biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic diseases with innovative single-pill combinations of existing treatments, designed for a balance of efficacy and safety, with the potential to improve patient adherence. Multi-mechanism, single-pill combinations offer the potential to bring significant improvements in clinical outcomes with cardiometabolic disorders, including hypertension, which remain among the leading causes of premature death and disability worldwide.
For more information, please visit www.george-medicines.com.
About Orient EuroPharma Co., Ltd.
Orient EuroPharma Co., Ltd. (OEP), established in 1982, has grown into a leading multinational pharmaceutical company headquartered in Taiwan. Listed on the Taipei Exchange (TPEx) since 2003. (4120.TW), OEP has built a strong presence across Southeast Asia, with extensive sales network in the region. OEP’s diversified portfolio spans prescription pharmaceuticals, oncology treatments, cosmeceuticals, and infant-to-adult nutrition and health products. The company also operates a dedicated subsidiary for innovative drug development and manufacturing. With integrated capabilities in pharmaceutical R&D, clinical trials, manufacturing, and regional marketing, OEP continues to advance healthcare solutions throughout Taiwan and the broader Asia-Pacific region.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to George Medicines’ financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential. In addition, this press release also contains forward-looking statements relating to George Medicines’ growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including George Medicines’ ability to successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of drug candidates.
Media contacts
ICR Healthcare
David Daley, Lindsey Neville, Tom Daniel
georgemedicines@icrhealthcare.com; Tel: +44 (0) 203 709 5700
